Fexofenadine Composition for Multi-Mechanism Neuroprotection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative diseases such as Parkinson's and Alzheimer's are inadequate in preventing or reversing neuronal damage and death, and existing antihistamines like fexofenadine have not been explored for their neuroprotective potential.
Innovation Solution
A pharmaceutical composition containing fexofenadine is developed to inhibit dopaminergic neuron death, reduce inflammation-mediated neuronal damage, inhibit α-synuclein aggregate formation, and suppress astrocyte activation, thereby protecting neurons and potentially treating neurodegenerative diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments (cell transplantation, surgical procedures) are used to treat neurodegenerative diseases, then treatment options are provided, but risk factors and side effects increase and no treatment can actually prevent neuron damage or death
Solution Approach 1:
The patent uses fexofenadine, a commercially available antihistamine drug, as a simple and safe treatment option. This drug is already approved for other indications and has a well-established safety profile, avoiding the high risks and side effects associated with cell transplantation and surgical procedures while providing effective neuroprotective benefits
Solution Approach 2:
The patent identifies fexofenadine as an intermediary substance that mediates neuroprotection through H1 receptor blocking activity. This drug acts as a mediator between external harmful factors (neurotoxins, inflammation) and neuronal cells, preventing damage without requiring invasive procedures or carrying significant risks
2Reliability
If first-generation antihistamines are used, then H1 blocking activity is achieved, but sedative effects increase due to blood-brain barrier penetration
Solution Approach 1:
The patent transitions from first-generation to second-generation antihistamines, specifically using fexofenadine, which changes the pharmacological parameters of the drug. This parameter change includes improved pharmacokinetic properties, reduced blood-brain barrier penetration, and maintained H1 blocking activity, thereby eliminating sedative effects while preserving therapeutic efficacy
Solution Approach 2:
The patent extracts the essential H1 blocking activity from first-generation antihistamines and separates it from the sedative side effects caused by blood-brain barrier penetration. By selecting fexofenadine, the patent obtains the useful H1 blocking function while excluding the harmful sedative effect, achieving functional separation of beneficial and adverse properties
3Adaptability or versatility
If no treatment can prevent neuron damage mechanism complexity is high, then comprehensive treatment coverage is attempted, but treatment development remains unsuccessful
Solution Approach 1:
The patent demonstrates that fexofenadine has multi-functional neuroprotective effects, including preventing dopaminergic neuron death, reducing inflammation-mediated damage, inhibiting α-synuclein aggregate formation, and suppressing astrocyte activation. This single drug provides comprehensive coverage for multiple mechanisms of neuronal damage, achieving universal protection without requiring complex combination therapies
Solution Approach 2:
The patent segments the complex neurodegenerative process into distinct mechanisms (dopaminergic neuron death, inflammation-mediated damage, α-synuclein aggregation, astrocyte activation) and shows that fexofenadine addresses each mechanism separately through different pathways, making the treatment approach manageable and comprehensive despite the underlying complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Fexofenadine demonstrates significant neuroprotective effects by improving behavioral abilities, extending lifespan, and reducing neuronal damage in animal models of neurodegenerative diseases.
Implementation Method 1
fexofenadine acts as a selective peripheral H1 blocker
Implementation Method 2
inhibiting inflammation-mediated neuronal damage or neuronal degeneration
Implementation Method 3
inhibiting α-synuclein Ser-129 phosphorylation aggregate formation
Data Source
AI summary
The present invention relates to a composition for prevention, alleviation, or treatment of neurodegenerative diseases, comprising fexofenadine. Fexofenadine, a compound already commercialized for pharmacological purposes, has proven to be safe, demonstrated significant improvements in behavioral abilities when administered to a neurodegenerative disease model, and exhibits neuroprotective effects of inhibiting the death of dopaminergic neurons, reducing damage to inflammation-mediated neurons or neuronal degeneration, preventing the formation of α-synuclein aggregates, and suppressing the abnormal increase and activation of astrocytes, and has the effect of extending the lifespan in the degenerative neurological disease model. Thus, the composition according to the present invention can be advantageously used for preventing, alleviating, or treating neurodegenerative diseases.